Clinical trials: Advanced Tumors
Recurrent CNS Tumors, Brain Cancer
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Background: Primary central nervous system (CNS) tumors grow in the brain and spinal cord. These tumors are rare, but they are difficult to treat and often fatal.
- Conditions
- Recurrent CNS Tumors, Brain Cancer, Gliomas, IDH-wildtype Gliomas
- Trial name
- NCT07374692
- Testing
- SmartMatch testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Liver Cancer
Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma
Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Advanced Adult Hepatocellular Carcinoma, Cirrhosis, Liver
- Trial name
- NCT04576572
- Where
- Turkey (Türkiye)
- Volunteers
- 424 people
- Sponsor
- Inonu University
Malignancy, Pain
Real-time Cancer Pain Assessment and Intervention
This study aim at the advanced malignant tumor patients who suffer from cancer pain, investigate the current status of cancer pain treatment, and study the effects in pain control and quality of life improvement using the method…
- Trial name
- NCT01914107
- Testing
- real-time monitoring and instruction of cancer pain, standard cancer pain care
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Advanced Cancer
A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT02889445
- Testing
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Where
- United States
- Sponsor
- DEKK-TEC, Inc.
Advanced Cancer
Bendamustine and Bevacizumab for Advanced Cancers
The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer.
- Trial name
- NCT01152203
- Testing
- Bendamustine, Bevacizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Rectal Cancer (LARC)
AI-Based Prediction of Pathological Response in Rectal Cancer Patients Receiving Total Neoadjuvant Therapy
This study aims to better understand how body composition, inflammation, and nutrition affect how rectal cancer responds to treatment.
- Trial name
- CINR-AI (NCT07049627)
- Testing
- Total Neoadjuvant Therapy (TNT)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 93 people
- Sponsor
- Ankara Etlik City Hospital
Gastric Cancer
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer deaths in the world. In spite of the progresses made in the diagnosis and treatment of gastric cancer in the past decades, the prognosis is…
- Trial name
- NCT04086888
- Where
- 2 sites in China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Breast Neoplasms, Fever
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
This is a prospective, randomized Phase III trial of FLAC chemotherapy with GM-CSF versus PIXY321 in advanced breast cancer. The primary endpoints of this study will be the duration of thrombocytopenia and the time to recovery of…
- Conditions
- Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia
- Trial name
- NCT00001338
- Testing
- FLAC chemotherapy with GM-CSF
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00416858
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Volunteers
- 40 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Cervical Cancer, Ovarian Cancer
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory…
- Trial name
- NCT00002478
- Testing
- etoposide
- Where
- 47 sites in United States
- Sponsor
- Gynecologic Oncology Group
NSCLC Stage IV, NSCLC Stage IIIB
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
This study aims to understand the metastasis in advanced NSCLC through comparing genomic and transcriptomic patterns between the circulating tumor cells and metastatic tumor cells by single cell sequencing analysis.
- Trial name
- NCT04932343
- Testing
- cohort study
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
- Trial name
- NCT03524326
- Testing
- Lenvatinib Pill, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure.
- Trial name
- NCT00026169
- Testing
- imatinib mesylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Central Nervous System Tumor
Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults
Phase I/II, open, prospective clinical trial, historically controlled. The objective is to evaluate the safety and, as a secondary measure, the efficacy of an experimental treatment based on a cellular therapy (vaccination with…
- Trial name
- DEND/TIA (NCT02496520)
- Testing
- dendritic cells, Surgery as needed by the patient´s tumor and stage, Chemotherapy as needed by the patient´s tumor and stage
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Recurrent Renal Cell Cancer, Renal Cell Carcinoma
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic…
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00684996
- Testing
- etaracizumab, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm, Desmoid Tumor
Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.
- Trial name
- NCT02955446
- Testing
- PF-03084014
- Where
- United States
- Sponsor
- University of Colorado, Denver
Non-small Cell Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for…
- Trial name
- NCT00050973
- Testing
- bexarotene
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 623 people
- Sponsor
- Eisai Inc.
Cervical Cancer Stage IIIB, Treatment Outcome
Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients
Cross-sectional Feasibility study on all consecutive patients of locally advanced cancer of the cervix or vault treated entirely at Tata Memorial Centre with curative intent radiation or chemoradiation.
- Conditions
- Cervical Cancer Stage IIIB, Treatment Outcome, Follow up, QUESTIONNAIRE
- Trial name
- NCT03477240
- Volunteers
- 300 people
- Sponsor
- Tata Memorial Hospital
Prostate Cancer
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer
- Trial name
- NCT02911350
- Testing
- Hormone Suppressors, Paclitaxel, Radiation Therapy
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Gastrointestinal Stromal Tumors
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients.
- Trial name
- NCT01396148
- Testing
- sunitinib malate dose escalation, sunitinib malate
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 6 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.